These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17274475)

  • 1. [Non-alcoholic fatty liver disease].
    Wójcik K; Piekarska A
    Pol Arch Med Wewn; 2006 Feb; 115(2):172-81. PubMed ID: 17274475
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [NASH -- nonalcoholic steatohepatitis].
    Blechacz B; Stremmel W
    Z Gastroenterol; 2003 Jan; 41(1):77-90. PubMed ID: 12541180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: Non-alcoholic fatty liver disease.
    Alba LM; Lindor K
    Aliment Pharmacol Ther; 2003 Apr; 17(8):977-86. PubMed ID: 12694079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder.
    Malnick SD; Beergabel M; Knobler H
    QJM; 2003 Oct; 96(10):699-709. PubMed ID: 14500857
    [No Abstract]   [Full Text] [Related]  

  • 6. NASH/NAFLD management.
    James OF
    Acta Gastroenterol Belg; 2002; 65(4):200-3. PubMed ID: 12619426
    [No Abstract]   [Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease and cardiovascular risk].
    Abel T; Fehér J
    Orv Hetil; 2008 Jul; 149(28):1299-305. PubMed ID: 18617457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Abdominal obesity: metabolic complications and consequences for the liver].
    Oldenburg B; Pijl H
    Ned Tijdschr Geneeskd; 2001 Jul; 145(27):1290-4. PubMed ID: 11475019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.
    Manousou P; Kalambokis G; Grillo F; Watkins J; Xirouchakis E; Pleguezuelo M; Leandro G; Arvaniti V; Germani G; Patch D; Calvaruso V; Mikhailidis DP; Dhillon AP; Burroughs AK
    Liver Int; 2011 May; 31(5):730-9. PubMed ID: 21457446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease].
    Kim MY; Baik SK
    Korean J Hepatol; 2008 Mar; 14(1):1-3. PubMed ID: 18367852
    [No Abstract]   [Full Text] [Related]  

  • 11. [Non-alcoholic liver disease (NASH)].
    Maier KP
    Praxis (Bern 1994); 2006 Aug; 95(34):1267-9. PubMed ID: 16956020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis].
    Choi SY; Kim D; Kang JH; Park MJ; Kim YS; Lim SH; Kim CH; Lee HS
    Korean J Hepatol; 2008 Mar; 14(1):77-88. PubMed ID: 18367860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver: the hepatologic stakes and the metabolic stakes].
    Traverso M
    Ann Endocrinol (Paris); 2003 Dec; 64(6):478-80. PubMed ID: 15080158
    [No Abstract]   [Full Text] [Related]  

  • 14. Case report: nonalcoholic steatohepatitis in a teenage girl with type 2 diabetes.
    Nadeau K; Klingensmith G; Sokol RJ
    Curr Opin Pediatr; 2003 Feb; 15(1):127-31. PubMed ID: 12544284
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Afdhal NH
    JAMA; 2012 Aug; 308(6):608-16. PubMed ID: 22760235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.
    James OF; Day CP
    J Hepatol; 1998 Sep; 29(3):495-501. PubMed ID: 9765002
    [No Abstract]   [Full Text] [Related]  

  • 17. [Nonalcoholic steatohepatitis: epidemiology, diagnosis and treatment].
    Tilg H
    Dtsch Med Wochenschr; 2001 Apr; 126(16):467-71. PubMed ID: 11360453
    [No Abstract]   [Full Text] [Related]  

  • 18. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-alcoholic steatohepatitis: natural history and diagnosis].
    Larrey D
    Gastroenterol Clin Biol; 2003; 27(8-9):793-8. PubMed ID: 14586250
    [No Abstract]   [Full Text] [Related]  

  • 20. Liver disease. Fat inflames the liver.
    Harv Health Lett; 2001 Feb; 26(4):4. PubMed ID: 11175451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.